Trial Profile
Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs VLA 15 (Primary) ; Alum
- Indications Lyme disease
- Focus Pharmacodynamics
- Sponsors Pfizer; Valneva
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 21 Nov 2020 This trial has been completed in Germany, according to European Clinical Trials Database.
- 10 Nov 2020 This trial has been completed in Austria, according to European Clinical Trials Database. (2020-10-02)